Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects

Leanne T Rodwell, Sandra D Anderson, Joanne Spring, Safaa Mohamed, J Paul Seale

Abstract

Background - Inhaled frusemide inhibits airway narrowing and causes a transient increase in forced expired volume in one second (FEV₁) during hypertonic saline challenge. This inhibitory effect could be secondary to prostaglandin release during challenge. The involvement of prostaglandins in the inhibitory action of frusemide during challenge with 4.5% NaCl was investigated by premedicating with indomethacin, a prostaglandin synthetase inhibitor.

Methods - Fourteen asthmatic subjects (eight women) aged 26.6 (range 18–56) years participated in a double blind, placebo controlled, crossover study. The subjects attended five times and inhaled 4.5% NaCl for 0.5, 0.75, 1, 1.5, 2, 4, 8, and 8 minutes, or part thereof, or until a provocative dose causing a 20% fall in FEV₁ (PD₂₀ FEV₁) was recorded. Indomethacin (100 mg/day) or placebo were taken three days before all visits, except control day. The FEV₁ was measured and frusemide (38.0 (6.4) mg, pH = 9) or vehicle (0.9% NaCl, pH = 9) were inhaled 10 minutes before the challenge. Bronchodilation was calculated as the percentage rise in FEV₁ from the prechallenge FEV₁, to the highest FEV₁, recorded during the challenge.

Results - Frusemide caused a fold increase in PD₂₀ FEV₁, compared with the vehicle which was similar in the presence of both indomethacin and placebo (3.7 (95% CI 2.0 to 7.3) versus 3.3 (2.0 to 5.4)). Frusemide, but not vehicle, also caused a transient percentage rise in FEV₁ during challenge with 4.5% NaCl which was not blocked by indomethacin (3.6% (1.2 to 6.0)) or placebo (3.1% (1.0 to 5.2)).

Conclusions - Inhaled frusemide inhibited airway narrowing and caused a transient increase in FEV₁ during challenge with 4.5% NaCl. These effects were not blocked by indomethacin, which suggests that the inhibitory action of frusemide is not secondary to prostaglandin release. (Thorax 1997;52:59–66)

Keywords: asthma, hypertonic saline, indomethacin, frusemide, bronchial responsiveness.

Inhaled frusemide inhibits the airway response to challenge with hypertonic saline in asthmatic subjects by a mechanism which may involve the blockade of chloride channels at several sites in the airways including mast cells, epithelial cells, and nerves. The inhibitory effect of frusemide on hypertonic saline challenge could also be attributed in part to its potential to release prostaglandin E₂ (PGE₂), which may indirectly relax airway smooth muscle. A hypertonic stimulus alone also has the potential to release PGE₂ from epithelial cells. The combination of frusemide and a hypertonic stimulus may enhance the release of PGE₂, resulting in the transient bronchodilation observed by Rodwell and colleagues in six of the 11 asthmatic subjects they studied.

There are several reasons why PGE₂ may be the cause of the transient bronchodilation: (1) human airway epithelium releases PGE₂; (2) frusemide stimulates PGE₂ production; (3) the protective effect of inhaled frusemide against airway narrowing caused by exercise in asthmatic subjects is inhibited by indomethacin, a drug which inhibits the synthesis of PGE₂; and (4) when PGE₂ is inhaled by normal subjects five minutes before histamine challenge there is a delay in airway narrowing similar to the delay observed during challenge with 4.5% NaCl after inhaling frusemide.

If PGE₂ is responsible for the transient bronchodilation and the "braking effect" on airway narrowing caused by hypertonic saline challenge, then indomethacin, a cyclo-oxygenase inhibitor, taken before frusemide inhalation should block the transient bronchodilation and the delay in airway narrowing.

The aim of this study was to investigate the role of prostaglandins in the transient bronchodilation caused by frusemide during challenge with 4.5% NaCl inhalation in asthmatic subjects.

Methods

Subjects

Fourteen asthmatic subjects (eight women) with a mean age (range) of 26.6 (18–56) years attended the respiratory investigation unit on five occasions with at least four days between visits. Subjects had a baseline forced expiratory volume in one second (FEV₁) of 62–90% of the predicted value and/or a history of a greater than 10% reversibility in FEV₁ after inhaling a β₂ adrenoceptor agonist. To be eligible for the study subjects had to record at least a 20% fall in FEV₁ after inhaling 4.5% NaCl on the control day. Subjects were excluded from the study if they had a history of respiratory symptoms after taking non-steroidal...
Table 1 Anthropometric details, prechallenge FEV₁, PD₂₀ FEV₁ on control day, asthma medications, dose of inhaled corticosteroids and time on this dose (n=14)

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Sex</th>
<th>Age (years)</th>
<th>FEV₁ control (% pred)</th>
<th>PD₂₀ FEV₁ control (ml)</th>
<th>Asthma medication</th>
<th>Dose of ICS (µg)</th>
<th>Time on this dose (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>27</td>
<td>63.7</td>
<td>3.7</td>
<td>S,BUD</td>
<td>1000</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>19</td>
<td>82.2</td>
<td>6.3</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>19</td>
<td>97.4</td>
<td>3.3</td>
<td>TO</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>19</td>
<td>87.2</td>
<td>8.5</td>
<td>S,BDP</td>
<td>400</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>53</td>
<td>70.0</td>
<td>5.0</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>56</td>
<td>88.0</td>
<td>2.9</td>
<td>S,BUD</td>
<td>800</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>20</td>
<td>86.3</td>
<td>8.6</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>23</td>
<td>82.9</td>
<td>4.4</td>
<td>S,BUD</td>
<td>2400</td>
<td>24</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>25</td>
<td>92.5</td>
<td>11.2</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>24</td>
<td>79.2</td>
<td>1.0</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>18</td>
<td>62.7</td>
<td>1.0</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>18</td>
<td>96.3</td>
<td>5.7</td>
<td>S,BUD</td>
<td>2000</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>21</td>
<td>85.4</td>
<td>1.1</td>
<td>S,BDP</td>
<td>400</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>30</td>
<td>86.0</td>
<td>21.1</td>
<td>S</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Mean 26.6 82.8 (SE 2.9) 4.2 *(95% CI 2.5 to 7.1)

Range 18–56

FEV₁ = forced expiratory volume in one second; PD₂₀ FEV₁ = dose of 4.5% NaCl aerosol (ml) causing a 20% fall in FEV₁; ICS = inhaled corticosteroids; S = salbutamol; BUD = budesonide; TO = terbutaline oral; BDP = beclomethasone dipropionate.

Only one subject (no. 3) was taking oral asthma medication.

* Geometric mean.

anti-inflammatory drugs (NSAIDs) or if they had a history of gastric ulcers. Anthropometric details, the FEV₁ measured as a percentage of the predicted value on the control day, the dose of saline required to provoke a fall in FEV₁ of over 20% (PD₂₀ FEV₁, ml) on the control day, and regular asthma medications are given in table 1.

Beta₂ adrenoceptor agonists were withheld for at least six hours before the 4.5% NaCl challenge. Six of the 14 subjects were taking inhaled corticosteroids on a daily basis for at least three months before the commencement of the study and the dose remained unchanged for the duration of the study. All subjects were atopic, having positive skin reactions to one or more of eight common allergens. Subjects were asked about recent symptoms of wheeze or dyspnoea. If an increase in these symptoms occurred in the previous 24 hours then testing did not proceed. No subject had a chest infection during the four weeks prior to the control visit.

The protocol was fully explained and written informed consent was obtained from each subject. The study was approved by the Central Sydney Health Area ethics committee.

FRUSEMIDE AND ITS VEHICLE

Ampoules of frusemide (Lasix; Hoechst AG, Germany), each containing 20 mg frusemide in 2 ml (10 mg/ml), with a pH of 9, were used in the study. The vehicle was 0.9% NaCl adjusted daily by the investigator to a pH of 8.9–9.2 by adding sodium hydroxide dissolved in 0.9% NaCl. A pH meter (Radiometer PHM 62, Copenhagen, Denmark) was used to measure the pH of the frusemide and its vehicle. The osmolality of the frusemide and its vehicle was 303 mosmol as measured by freezing point depression (Advanced Cryomatic Osmometer, Model Advanced Instruments, Massachusetts, USA). Once the osmolality of the vehicle solution was adjusted, both the frusemide and the vehicle were drawn up in separate 10 ml syringes and given to a pharmacist for assignment according to a randomisation code.

One syringe with either the frusemide or vehicle was then returned to the investigator to administer to the subject. This was a double blind, vehicle controlled, randomised, cross-over study.

DELIVERY OF AEROSOL FRUSEMIDE AND ITS VEHICLE

The Fisoneb ultrasonic nebuliser (Fisons Corporation, Rochester, New York, USA) producing a dense aerosol with a mass median aerodynamic diameter of 4.7 μm was used to deliver both the frusemide and the vehicle.

In order to give a dose of frusemide similar to that used in a previous study, 6 ml of frusemide or vehicle was placed in the Fisoneb. Subjects inhaled the aerosols for 7–9 minutes via a mouthpiece while wearing nose clips. The unit was weighed (Sartorius Analytic, Gottingen, Germany) before and after nebulisation and a stopper placed in the output hole during weighing to reduce loss of volume by evaporation. The difference in weight change was recorded as the amount of frusemide or vehicle nebulised. The mean (SD) amount of frusemide nebulised for the challenge was 38.0 (6.4) mg (n=26). On two occasions subjects salivated profusely back into the Fisoneb during nebulisation so these values were not included in the calculation of the mean dose of frusemide delivered.

INDOMETHACIN AND ITS PLACEBO

Subjects ingested 50 mg of indomethacin (Arthrexin, Alphapharm, Australia) twice a day (100 mg/day) or a placebo (glucose powder in an identical capsule) for three days before each challenge visit.

Subjects were given 12 capsules of either 25 mg indomethacin or placebo at the end of the control day and visits 1, 2, and 3 and instructed to take two capsules twice a day in the morning and at night for three days before visits 1, 2, 3, and 4. The last two capsules were to be taken approximately 1.5 hours before coming to the laboratory.
AIRWAY SENSITIVITY TO INDOMETHACIN

All subjects were assessed for airway sensitivity to oral indomethacin on the control visit. After recording at least a 20% fall in FEV1 to 4.5% NaCl challenge on the control day subjects recovered spontaneously over a one hour period after challenge. They were given either a peak flow meter (Clement Clarke International Ltd, Harlow, Essex, UK) or an airflow meter and instructed how to measure and record their expiratory flow rates. The flow rate was measured before ingesting two 25 mg capsules (50 mg) of indomethacin and every hour for six hours after ingesting the capsules. The first and second hourly measurements were taken in the laboratory with subsequent measurements being carried out at home. Subjects were excluded from the study if there was a greater than 21% variability from the expiratory flow rate measured before indomethacin.

MEASUREMENT OF THROMBOXANE B2 (TXB2) PLASMA LEVELS

The extent to which indomethacin inhibited cyclo-oxygenase activity was determined indirectly by measuring plasma levels of thromboxane B2 (TXB2) by radioimmunoassay (RIA). TXB2 was measured because it is a stable metabolite of arachidonic acid and is found in large quantities in plasma.

COLLECTION AND PROCESSING OF VENOUS BLOOD SAMPLES

On visits 1, 2, 3, and 4 a 10 ml venous blood sample was taken from the forearm of each subject in the 10 minute period after the 4.5% NaCl challenge. The blood was immediately transferred into a 10 ml prechilled siliconised glass test tube coated with a solution of 4.5 mM EDTA and 5 µg/ml of indomethacin dissolved in ethanol. The tube was capped and gently inverted several times to ensure adequate mixing of the blood sample, EDTA, and indomethacin. This sample was immediately placed in ice chips and within 10 minutes was centrifuged for 10 minutes at 2500 rpm at 4°C. The plasma from the sample was then pipetted into two 2.5 ml cryogenic tubes and “snap frozen” in liquid nitrogen for approximately one minute. The frozen sample was removed from the liquid nitrogen and stored in a deep freeze at −80°C. At a later date the plasma samples were thawed and plasma levels of TXB2 were measured using RIA (NEN Inc, Biomedical Products Department, Boston, Massachusetts, USA).

CHALLENGE WITH 4.5% NaCl AEROSOL

The protocol used to perform the 4.5% NaCl challenge was similar to that described by Rodwell and colleagues, although the initial inhalation periods were of a shorter duration in order to optimise the detection of changes in FEV1 during the initial stage of the challenge. Subjects inhaled the challenge aerosol for 0.5 minutes, waited one minute, then spirometric tests were performed. If there was a 20% fall in FEV1 from the baseline value the challenge was stopped and the subject included in the study. If a 20% fall was not recorded the challenge continued for further intervals of 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, 8.0, and 8.0 minutes, or part thereof, or until a fall in FEV1 of at least 20% was recorded.

STUDY DESIGN

Subjects were required to attend the laboratory on five occasions with a minimum of four days separating all visits because indomethacin has a half life of 2–11 hours. Drug administration was randomised so that each subject received either indomethacin and frusemide/vehicle or placebo and frusemide/vehicle.

CONTROL DAY

Eligibility for the study was assessed on the control day. On arrival at the laboratory spirometric tests (Minato Autospirometer AS500, Osaka, Japan) were performed in triplicate and then repeated 10 minutes later. If there was a less than 10% variation in the FEV1 over 10 minutes the airways were considered stable and the 4.5% NaCl challenge was performed. When a 20% fall from baseline FEV1 was recorded the challenge was stopped and the PD20 FEV1 (ml) calculated. Lung function spontaneously recovered over the following 60 minutes and then airway sensitivity to 50 mg of oral indomethacin was assessed by measuring expiratory flow rates over the following six hours.

VISITS 1, 2, 3, AND 4

On arrival at the laboratory spirometric tests were performed in triplicate and repeated 10 minutes later. If there was less than 10% variation in these measurements subjects inhaled the frusemide or its vehicle via a Fisoneb ultrasonic nebuliser. Ten minutes later the spirometric tests were repeated in triplicate and the highest recorded FEV1 was used as the baseline FEV1 for the 4.5% NaCl challenge. The 4.5% NaCl challenge was stopped when either a fall of more than 20% in FEV1 was recorded or the last dose of 4.5% NaCl aerosol was nebulised. A venous blood sample was taken for the measurement of TXB2 plasma levels in the first 10 minutes after the 4.5% NaCl challenge.

Before leaving the laboratory subjects were given either the indomethacin or placebo capsules for the next visit. They were instructed to take their indomethacin 1.5 hours before coming to the laboratory as peak plasma concentrations are reached approximately two hours after taking indomethacin.

ANALYSIS OF DATA

Effect of inhaled frusemide and its vehicle on baseline FEV1, prechallenge

The effect of inhaling frusemide or its vehicle on baseline lung function was assessed by calculating the difference in FEV1 before and 10 minutes after inhaling these aerosols. This was
calculated on the days the placebo for indomethacin was given.

**PD\textsubscript{20} FEV\textsubscript{1} to 4.5\% NaCl challenge**
The provocative dose of 4.5\% NaCl (ml) causing a 20\% fall from the baseline FEV\textsubscript{1} (PD\textsubscript{20} FEV\textsubscript{1}) was calculated and reported as the geometric mean with 95\% confidence intervals. Changes in PD\textsubscript{20} FEV\textsubscript{1} between study days were reported as the fold change with 95\% confidence intervals.

**Percentage rise in FEV\textsubscript{1} during challenge**
The transient bronchodilation or the percentage rise in FEV\textsubscript{1} from the baseline pre-challenge FEV\textsubscript{1} during challenge (% rise) was calculated by subtracting the highest FEV\textsubscript{1} (l) recorded during challenge from the pre-challenge FEV\textsubscript{1} (l) and expressing this difference as a percentage of the prechallenge FEV\textsubscript{1} (l).

**Maximum percentage rise in FEV\textsubscript{1} during challenge**
The maximum percentage rise recorded on the two days frusemide was inhaled was calculated. At the greater of the two values the cumulative dose of 4.5\% NaCl (ml) was recorded, thus giving an indication when the maximum percentage rise in FEV\textsubscript{1} occurs during challenge. The significance of the maximum percentage rise in FEV\textsubscript{1} during challenge with 4.5\% NaCl was then tested by comparing the percentage rise on the frusemide day with the percentage rise on the vehicle day at the same delivered dose of 4.5\% NaCl. For example, if the maximum percentage rise in FEV\textsubscript{1} occurred after 5 ml on the placebo/frusemide day, then it was compared with the corresponding percentage rise in FEV\textsubscript{1} at 5 ml on the placebo/vehicle day. The comparison of the maximum percentage rise between inhaled frusemide and vehicle was therefore performed only in the presence of indomethacin or placebo.

**Differences in plasma TXB\textsubscript{2} levels**
Plasma levels of TXB\textsubscript{2} (pg/ml plasma) were compared between the indomethacin and the placebo study days.

**Relationship between TXB\textsubscript{2} levels and percentage rise in FEV\textsubscript{1}**
The mean difference in plasma TXB\textsubscript{2} levels on the placebo/vehicle and indomethacin/frusemide days and the mean difference in the percentage rise in FEV\textsubscript{1} on the placebo/vehicle and indomethacin/frusemide days were calculated. A Spearman’s rank correlation was then performed on these calculated differences.

**Statistical analysis**
Data are presented as mean with 95\% confidence intervals or the mean and its range. The PD\textsubscript{20} FEV\textsubscript{1} (ml) to 4.5\% NaCl challenge is summarised as the geometric mean with 95\% confidence intervals. A Student’s paired \(t\) test was used to test differences between paired mean data and a Pearson’s or Spearman’s correlation test for relationships between variables. Differences were considered significant at \(p<0.05\).

**Results**

**FEV\textsubscript{1} on arrival: control day and visits 1–4**
On arrival at the laboratory there was less than a 20\% difference in the FEV\textsubscript{1} between the control day and subsequent visits.

**Effect of inhaled frusemide and indomethacin on baseline FEV\textsubscript{1}: prechallenge**
There was a small increase of 0.06 l (0 to 0.12) from baseline FEV\textsubscript{1} 10 minutes after inhaling frusemide and a decrease of 0.07 l (−0.13 to −0.01) after inhaling the vehicle (\(p=0.03\), \(n=14\)). These changes were considered not clinically significant.

**Effect of PD\textsubscript{20} FEV\textsubscript{1} of challenge with 4.5\% NaCl**
On the days frusemide was inhaled there was a significant increase in the PD\textsubscript{20} FEV\textsubscript{1} to 4.5\% NaCl challenge. In the presence of indomethacin the mean PD\textsubscript{20} FEV\textsubscript{1} increased from 5.4 ml (2.9 to 9.9) after inhaling the vehicle to 20.2 ml (14.5 to 28.4) after inhaling frusemide (\(p<0.001\), \(n=14\)), which represented a 3.7 (2.0 to 7.3) fold increase. In the presence of placebo the PD\textsubscript{20} FEV\textsubscript{1} increased from 4.9 ml (2.5 to 9.6) after inhaling the vehicle to 16.3 ml (11.2 to 23.7) after inhaling frusemide (\(p<0.001\), \(n=14\)), a 3.3 (2.0 to 5.4) fold increase.

The fold increase in PD\textsubscript{20} FEV\textsubscript{1} caused by frusemide was similar in the presence of indomethacin and placebo (3.7 (2.0 to 7.3) versus 3.3 (2.0 to 5.4); \(p=0.61\), \(n=14\)). Indomethacin therefore had no effect on the increase in PD\textsubscript{20} FEV\textsubscript{1} caused by frusemide.

When the vehicle was inhaled there was no significant difference in the PD\textsubscript{20} FEV\textsubscript{1} between the indomethacin and placebo days with the mean fold difference being 0.9 (0.6 to 1.4); \(p=0.66\) (\(n=14\)).

There was a range of asthma severity within the group (table 1) with the mean PD\textsubscript{20} FEV\textsubscript{1} being 4.2 ml (2.5 to 7.1) which is considered to be in the moderate range. Three subjects had severe asthma (PD\textsubscript{20} FEV\textsubscript{1} ≤ 2 ml), six had moderate asthma (PD\textsubscript{20} FEV\textsubscript{1} > 2 ml and ≤ 6 ml), and five had mild asthma (PD\textsubscript{20} FEV\textsubscript{1} > 6 ml). Two subjects (11 and 13) contracted a mild chest infection after visit 3 and therefore there was a period of 28 and 29 days, respectively, between visits 3 and 4.

**Percentage rise in FEV\textsubscript{1} during challenge**
Frusemide, when inhaled by asthmatic subjects before challenge with 4.5\% NaCl, caused a transient rise in FEV\textsubscript{1} which was not blocked by indomethacin or its placebo (3.6\% (1.2 to 6.0) versus 3.1\% (1.0 to 5.2)) with a mean
Inhaled frusemide, oral indomethacin and airway response to hypertonic saline in asthmatics

The prechallenge FEV₁ recorded after subjects that prostaglandins are involved in the transient -11.2 to -4.8% (6.4 to 1.2); \( p = 0.002 \) (\( n = 28 \)). The results suggest that challenge maximises the opportunity to observe indomethacin inhibited but did not completely transient bronchodilation during challenge. In block the formation of plasma TXB₂. fact, there was an inverse correlation between the 3.7-fold decrease in PD₂₀ \( \) FEV₁ on the

The maximum percentage rise occurred on the placebo/frusemide day in nine of the 14 subjects and on the indomethacin/frusemide day in the remaining five subjects. At the common nebulised dose of saline (1.96 ml (1.1 to 3.34)) there was a 4.9% (2.6 to 7.1) rise from baseline \( \) FEV₁ on the frusemide day compared with a fall of -9.6% (-13.8 to -5.4) from baseline \( \) FEV₁ on the corresponding vehicle day. The mean percentage rise between the \( \) percentage rise from baseline \( \) FEV₁ in the presence of frusemide and the fall from the presence of vehicle was 14.5% (9.4 to 19.6); \( p = 0.001 \) (\( n = 14 \)).

**Discussion**

The results show that the transient bronchodilation caused by inhaled frusemide during the initial stages of airway challenges has been reproduced in this study and that indomethacin had no effect on the decrease in airway sensitivity to 4.5% NaCl challenge caused by frusemide. It is therefore unlikely that prostaglandins are involved in the transient bronchodilation and the decrease in airway sensitivity to 4.5% NaCl challenge as indomethacin, a prostaglandin synthetase inhibitor, is not effective in inhibiting these responses. These findings are supported by the results of studies performed in human nasal mucosa where frusemide did not cause an increase in PGE₂ levels.

The significant bronchodilation during challenge observed in the presence of approximately 40 mg frusemide occurred after 2 ml of 4.5% NaCl had been nebulised. This bronchodilation during challenge has not been described in previous studies where smaller doses of frusemide have been nebulised. With the inhalation of larger doses of frusemide (40–80 mg) bronchodilation has been observed. Thus, the protective effect of frusemide which we observed against airway challenge may be partly attributable to its bronchodilating action, but only at higher doses. This is the first study to investigate the transient bronchodilation observed in the presence of frusemide during 4.5% NaCl challenge in asthmatic subjects. During exercise challenge a single maximum stimulus dehydrates the airways and a dose-response curve cannot be constructed. Subtle changes in lung function would therefore be missed during exercise challenge. Also, if subjects were at their best lung function before the start of challenge then it is unlikely that bronchodilation would be observed during the challenge. All subjects in the present study were either at less than 90% of their predicted \( \) FEV₁ or were known to have at least a 10% increase in \( \) FEV₁ after inhaling a bronchodilator. Airways obstruction before challenge maximises the opportunity to observe transient bronchodilation during challenge. In fact, there was an inverse correlation between lung function and the transient bronchodilation caused by frusemide – that is, the lower the prechallenge lung function the greater the percentage rise in \( \) FEV₁ during challenge.

Inhaled frusemide also caused a small increase in the prechallenge \( \) FEV₁, and an increase in the PD₂₀ \( \) FEV₁ to 4.5% NaCl aerosol, both of which were unaffected by premedication with indomethacin. This study shows that indomethacin has no effect on the decrease in airway sensitivity to 4.5% NaCl challenge caused by frusemide. The 3.3-fold decrease in PD₂₀ \( \) FEV₁ on the placebo day was not significantly different from the 3.7-fold decrease in PD₂₀ \( \) FEV₁ on the indomethacin day. Plasma TXB₂ levels were significantly lower on the days of indomethacin administration, indicating that subjects had taken their capsules as instructed.

We selected a dose of 100 mg/day indomethacin because it blocks refractoriness to

**MAXIMUM PERCENTAGE RISE IN FEV₁ DURING CHALLENGE**

The mean (95% CI) highest percentage rise in \( \) FEV₁ during 4.5% NaCl challenge was 4.9% (2.6 to 7.1) which occurred after (geometric mean with 95% CI) 1.96 ml (1.1 to 3.5) of 4.5% NaCl had been nebulised. The maximum percentage rise occurred on the placebo/frusemide day in nine of the 14 subjects and on the indomethacin/frusemide day in the remaining five subjects. At the common nebulised dose of saline (1.96 ml (1.1 to 3.34)) there was a 4.9% (2.6 to 7.1) rise from baseline \( \) FEV₁ on the frusemide day compared with a fall of -9.6% (-13.8 to -5.4) from baseline \( \) FEV₁ on the corresponding vehicle day. The mean percentage rise between the \( \) percentage rise from baseline \( \) FEV₁ in the presence of frusemide and the fall from the presence of vehicle was 14.5% (9.4 to 19.6); \( p = 0.001 \) (\( n = 14 \)).

**PLASMA TXB₂ LEVELS**

Plasma levels of TXB₂ measured in the presence of indomethacin were lower than the levels measured on the placebo day with the mean difference being 154.8 pg/ml (62.5 to 247.1); \( p = 0.002 \) (\( n = 28 \)). The results suggest that indomethacin inhibited but did not completely block the formation of plasma TXB₂.

**RELATIONSHIP BETWEEN TXB₂ LEVELS AND PERCENTAGE RISE IN FEV₁**

Indomethacin significantly reduced plasma TXB₂ levels compared with its placebo. The mean difference in plasma TXB₂ levels between the indomethacin and placebo days was 73 pg/ml (17.0 to 129.4); \( p = 0.01 \) (\( n = 14 \)). The percentage rise during challenge with 4.5% NaCl was greater in the presence of frusemide than its vehicle with the mean difference being -5.8% (-11.2 to -0.4); \( p = 0.04 \) (\( n = 14 \)). There was, however, no significant correlation between the reduction in plasma TXB₂ levels and the effect of frusemide on lung function during challenge (\( r_s = 0.13 \); \( p = \text{NS} \), \( n = 14 \)).

Individual dose-response curves for the five study days for the 14 subjects who participated in this study are shown in fig 1.
Figure 1  Individual dose-response curves representing the percentage fall from the prechallenge FEV₁ on the control and four study days for the 14 subjects participating in the study. □ = control day; ● = indomethacin/frusemide day; ■ = indomethacin/vehicle day; ▲ = placebo/frusemide day; ○ = placebo/vehicle day.
Inhaled frusemide, oral indomethacin and airway response to hypertonic saline in asthmatics

ultrasonically nebulised distilled water which is thought to be mediated by prostaglandins. This result suggests that the prostaglandins released in the airways by non-isotonic aerosol challenge are inhibited by taking 100 mg/day of oral indomethacin for three days before challenge. If inhaled frusemide (40 mg) enhances airway prostaglandin release, causing a rise in FEV1, during hyperosmolar saline challenge, then 100 mg/day indomethacin should at least partially inhibit prostaglandin production and reduce the rise in FEV1, during challenge.

Investigators have suggested that bronchoconstrictor prostaglandins are released during indirect airway challenges such as water and metabisulphite. When these investigators gave either oral or inhaled cyclo-oxygenase inhibitors before challenge there was a significant improvement in airway sensitivity to these challenges. This improvement was enhanced in the presence of frusemide. In our study indomethacin did not improve airway sensitivity when taken before 4.5% NaCl challenge or when taken in combination with inhaled frusemide. This suggests that bronchoconstricting prostaglandins are not released during challenge with 4.5% NaCl or that adequate pulmonary cyclo-oxygenase inhibition was not achieved in all subjects. Our study, however, is the first to attempt to record objectively the effectiveness of cyclo-oxygenase inhibition by measuring TXB2 levels on both indomethacin and placebo days. Unlike previous studies, we have evidence to support the inhibition of prostaglandin production by indomethacin as there was a significant reduction in TXB2 levels on the days indomethacin was taken. What is uncertain is whether this dose was effective at reducing airway prostaglandin activity.

The fact that indomethacin had no effect on the transient bronchodilation observed in the presence of frusemide during 4.5% NaCl challenge suggests that PGE2 was not implicated in this response. Other substances that may be involved in the transient bronchodilation observed in these studies are vasoactive intestinal peptide (VIP) and nitric oxide (NO), possible neurotransmitters released from the inhibitory non-adrenergic non-cholinergic (iNANC) nervous system in human airways. The iNANC nervous system is the only known neural bronchodilator system found in the airways. A hypertonic stimulus has the potential to release sensory neuropeptides from rat trachea and human bronchial airways and an increase in airway osmolarity causes an increase in the discharge frequency of airway sensory nerves in dogs. It has been shown in vitro that VIP is released from canine intestinal tissue in response to a hypertonic stimulus. It is therefore conceivable that a hypertonic stimulus has the potential to cause the release of VIP and/or NO.

If these neurotransmitters are released in response to a hypertonic stimulus, then why was the transient bronchodilation during 4.5% NaCl challenge only observed in the presence of frusemide? There may be several possible explanations. Firstly, frusemide may delay the onset of airway narrowing by initially blocking the release of mast cell mediators while bronchodilating mediators such as VIP and NO are being released in response to the hypertonic stimulus. As the hypertonic stimulus continues, frusemide becomes ineffective at blocking mast cell mediator release and these bronchoconstricting mediators override the bronchodilating effect of VIP and/or NO. Secondly, frusemide may block the release of neurotransmitters from the excitatory non-adrenergic non-cholinergic nervous system (eNANC) such as substance P which causes contraction of bronchial smooth muscle. With the temporary blockade of eNANC neurotransmitters the iNANC system would be unopposed and this would account for the observed transient bronchodilation. Whether frusemide preferentially blocks the eNANC nervous system is uncertain as this action of frusemide has not been studied. Thirdly, the release of VIP in response to a hypertonic stimulus may be dependent upon blocking a frusemide sensitive chloride channel, possibly at airway sensory nerves.

Finally, a hypertonic stimulus in combination with frusemide may stimulate the release of bronchoconstricting mediators from airway epithelium. Studies performed in equine trachealis muscle have shown that frusemide inhibited cholinergic nerve stimulation; however, this response was dependent on the epithelium being intact. More recently Verleden and colleagues have shown, in human bronchial tissue where the epithelium had been removed, that frusemide in combination with indomethacin was effective in inhibiting cholinergic contraction of the tissue.

In conclusion, this study shows that prostaglandins are unlikely to be responsible for the transient bronchodilation observed in the presence of frusemide during 4.5% NaCl challenge in asthmatic subjects.

The authors thank Dr Jennifer Peat for her assistance with the statistical analysis and the Pharmacy department at Royal Prince Alfred Hospital, Sydney for their assistance in coding the drugs. This work was performed with funding from the NH and MRC of Australia (LR).


